Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum

Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced participation in the 2nd Annual CybeRx Series: Vaccine Forum on June 22, 2021. The fireside chat will feature discussions around NVX-CoV2373, Novavax's recombinant nanoparticle protein-based COVID-19 vaccine. The event will be moderated by Geoffrey Porges, with Novavax leaders Gregory M. Glenn and John J. Trizzino participating. This forum highlights Novavax's innovative approach to vaccine development, particularly in combating serious infectious diseases.

GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the upcoming 2^nd Annual CybeRx Series: Vaccine Forum. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Fireside chat details:
Date:	Tuesday, June 22, 2021
Time:	11:00 – 11:50 a.m. Eastern Time (ET)
Moderator:	Geoffrey Porges, M.B.B.S.
Novavax participants:	Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer

Please contact your SVP Leerink representative to view the session.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com

Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
Amy Speak | 617-420-2461
media@novavax.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-participate-in-fireside-chat-at-svb-leerink-cyberx-series-vaccine-forum-301315044.html

SOURCE Novavax, Inc.

FAQ

When is Novavax participating in the 2nd Annual CybeRx Series: Vaccine Forum?

Novavax will participate in the forum on June 22, 2021.

What will Novavax discuss at the CybeRx Series: Vaccine Forum?

Novavax will discuss its COVID-19 vaccine candidate, NVX-CoV2373.

Who is moderating the fireside chat for Novavax at the Vaccine Forum?

Geoffrey Porges will moderate the fireside chat.

Who are the Novavax participants at the CybeRx Series: Vaccine Forum?

Gregory M. Glenn and John J. Trizzino will represent Novavax.

What is the time for Novavax's fireside chat during the Vaccine Forum?

The chat is scheduled from 11:00 to 11:50 a.m. Eastern Time.